ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2513

Anti-Mullerian Hormone In Patients With Systemic Lupus Erythematosus

Chiara Tani1, Sabrina Vagnani2, Linda Carli3, Giovanni Gallo4, Maria Rita Sessa5, Chiara Baldini6, Alessandra Della Rossa7, Rosaria Talarico8, Francesca Strigini3, Marco Maccheroni5, Stefano Bombardieri3 and Marta Mosca3, 1Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, 2Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, 3Rheumatology Unit, University of Pisa, Pisa, Italy, 4Departement of Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, 5S. Chiara Hospital, Pisa, Italy, 6University of Pisa, Rheumatology Unit, Pisa, Italy, 7Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, 8Rheumatology Unit, Pisa, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: pregnancy and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic Lupus Erythematosus (SLE) frequently affects women in childbearing age; disease related factors and treatment can interfere with ovarian function. Anti-Mullerian-hormone (AMH) levels are considered a surrogate marker of the ovarian reserve in pre-menopausal women. In this study we aimed at evaluating AMH levels in SLE patients and at establishing possible correlations with disease variables, therapies and obstetrical history

Methods:

AMH levels were assessed in pre-menopausal SLE patients with an enzymatically amplified two-site immunoassay (AMH Gen II ELISA; Beckman Coulter). According to the published literature in healthy subjects, values 1 to 8 ng/mL indicate normal, values < 1ng/mL indicate reduced and <0.4 strongly reduced ovarian reserve. Demographic data, clinical variables, disease activity, ongoing therapies as well as cumulative glucocorticoids dosage (GC) and previous therapy with Cyclophsphamide (Cyc) at the time of AMH evaluation were collected from clinical charts. Obstetrical history and menopausal status at the end of follow up were also considered.

Results:

Seventy-five SLE patients were examined (mean age and disease duration 32.9±7 and 9.4 ±6 years respectively);  58 (77.3%) presented a history of renal involvement and 44 (58.6%) had received Cyc before AMH assay (mean cumulative dosage 7.31±6 g, intravenous in 33, oral in 8, both regimens in 3). The median time between the latest Cyc administration and AMH determination was 6.3 years (±5.5). At study entry, the mean GC dosage was 5.9 mg (±6.9) and the mean cumulative dosage was 14.9 (±11); 35 (46%) patients were receiving immunosuppressants. AMH values were within the normal ranges in 23 (30.6%) patients, reduced in 16 (21.3%) and strongly reduced in 36 (48%). AMH levels were inversely related to age (p=0.0001) and disease duration (p=0.004) and to previous therapy with Cyc (p=0.03). At the end of follow-up, 48 patients (64%) had at least one pregnancy and 4 (5%) were in menopause (2 premature ovarian failures). No relationships were observed between AMH levels and disease activity or cumulative GC. AMH levels were not correlated with the occurrence of pregnancy but were significantly associated with the number of pregnancies (p=0.03).

Conclusion:

In our cohort, a high percentage of patients presented low or very low levels of AMH; as expected, a significant decrease with age progression have been observed and previous therapy with Cyc seem to be important contributors. The association of AMH levels and the number of subsequent pregnancies supports the significance of this testing to assess ovarian reserve in these patients.


Disclosure:

C. Tani,
None;

S. Vagnani,
None;

L. Carli,
None;

G. Gallo,
None;

M. R. Sessa,
None;

C. Baldini,
None;

A. Della Rossa,
None;

R. Talarico,
None;

F. Strigini,
None;

M. Maccheroni,
None;

S. Bombardieri,
None;

M. Mosca,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-mullerian-hormone-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences